SpringWorks fixes 'minor data handling error' after March Form 483 for trial site linked to upcoming PDUFA
21 Aug 2023
The FDA issued SpringWorks Therapeutics a Form 483 on March 31, saying that the company’s own clinical trial protocols were not followed.
But SpringWorks COO Badreddin Edris told Endpoints News in a phone interview on Monday that “it was a minor data handling error on an exploratory endpoint that was corrected within a week in March and resulted in no impact on the data” that formed the basis of the company’s application for its first “pipeline-in-a-product” oncology treatment, the oral gamma secretase inhibitorgamma secretase inhibitor, dubbed nirogacestat, or Ogsiveo.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.